{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T14:05:04Z","timestamp":1775570704708,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,31]]},"DOI":"10.7759\/cureus.102693","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T12:10:09Z","timestamp":1769861409000},"source":"Crossref","is-referenced-by-count":1,"title":["Early-Onset Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Following First-Cycle Pembrolizumab: Diagnostic Challenges and Management Strategies"],"prefix":"10.7759","author":[{"given":"Ziad","family":"Gaafar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salma","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayoub","family":"Tantush","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Hesham Gamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saifaldeen  S","family":"Al-Badawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lamis","family":"Fahal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aly","family":"Abouslima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216687389","article-title":"Pembrolizumab-induced myasthenia gravis: a fatal case report","volume":"24","author":"March KL","year":"2018","unstructured":"March KL, Samarin MJ, Sodhi A, Owens RE. Pembrolizumab-induced myasthenia gravis: a fatal case report. J Oncol Pharm Pract. 2018, 24:146-9. 10.1177\/1078155216687389","journal-title":"J Oncol Pharm Pract"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2022.09.004","article-title":"Immune checkpoint inhibitor therapy in oncology: current uses and future directions: JACC: CardioOncology state-of-the-art review","volume":"4","author":"Tan S","year":"2022","unstructured":"Tan S, Day D, Nicholls SJ, Segelov E. Immune checkpoint inhibitor therapy in oncology: current uses and future directions: JACC: CardioOncology state-of-the-art review. JACC CardioOncol. 2022, 4:579-97. 10.1016\/j.jaccao.2022.09.004","journal-title":"JACC CardioOncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.875974","article-title":"Overview of checkpoint inhibitors mechanism of action: role of immune-related adverse events and their treatment on progression of underlying cancer","volume":"9","author":"Iranzo P","year":"2022","unstructured":"Iranzo P, Callejo A, Assaf JD, et al.. Overview of checkpoint inhibitors mechanism of action: role of immune-related adverse events and their treatment on progression of underlying cancer. Front Med (Lausanne). 2022, 9:875974. 10.3389\/fmed.2022.875974","journal-title":"Front Med (Lausanne)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01056-8","article-title":"Next generation of immune checkpoint inhibitors and beyond","volume":"14","author":"Marin-Acevedo JA","year":"2021","unstructured":"Marin-Acevedo JA, Kimbrough EO, Lou Y. Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol. 2021, 14:45. 10.1186\/s13045-021-01056-8","journal-title":"J Hematol Oncol"},{"key":"ref5","unstructured":"FDA approves pembrolizumab plus axitinib for advanced renal cell carcinoma. (2019). Accessed. January 31, 2026: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-pembrolizumab-plus-axitinib-advanced-renal-cell-c...."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2021.03.003","article-title":"Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy","volume":"126","author":"Goleva E","year":"2021","unstructured":"Goleva E, Lyubchenko T, Kraehenbuehl L, Lacouture ME, Leung DY, Kern JA. Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy. Ann Allergy Asthma Immunol. 2021, 126:630-8. 10.1016\/j.anai.2021.03.003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1738382","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"19","author":"Haugh AM","year":"2020","unstructured":"Haugh AM, Probasco JC, Johnson DB. Neurologic complications of immune checkpoint inhibitors. Expert Opin Drug Saf. 2020, 19:479-88. 10.1080\/14740338.2020.1738382","journal-title":"Expert Opin Drug Saf"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ensci.2021.100324","article-title":"Detect it so you can treat it: a case series and proposed checklist to detect neurotoxicity in checkpoint therapy","volume":"22","author":"Bolz S","year":"2021","unstructured":"Bolz S, Ramakrishnan T, Fleischer M, et al.. Detect it so you can treat it: a case series and proposed checklist to detect neurotoxicity in checkpoint therapy. eNeurologicalSci. 2021, 22:100324. 10.1016\/j.ensci.2021.100324","journal-title":"eNeurologicalSci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/874680","article-title":"Myasthenia gravis: a review","volume":"2012","author":"Jayam Trouth A","year":"2012","unstructured":"Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J. Myasthenia gravis: a review. Autoimmune Dis. 2012, 2012:874680. 10.1155\/2012\/874680","journal-title":"Autoimmune Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1987.tb51317.x","article-title":"The course of myasthenia gravis and therapies affecting outcome","volume":"505","author":"Grob D","year":"1987","unstructured":"Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci. 1987, 505:472-99. 10.1111\/j.1749-6632.1987.tb51317.x","journal-title":"Ann N Y Acad Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100317","article-title":"How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors","volume":"6","author":"Jordan B","year":"2021","unstructured":"Jordan B, Benesova K, Hassel JC, Wick W, Jordan K. How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors. ESMO Open. 2021, 6:100317. 10.1016\/j.esmoop.2021.100317","journal-title":"ESMO Open"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13442","article-title":"Immune checkpoint inhibitor-associated myositis and myasthenia gravis overlap: understanding the diversity in a case series","volume":"17","author":"Wong EY","year":"2021","unstructured":"Wong EY, Yong MH, Yong KP, et al.. Immune checkpoint inhibitor-associated myositis and myasthenia gravis overlap: understanding the diversity in a case series. Asia Pac J Clin Oncol. 2021, 17:e262-7. 10.1111\/ajco.13442","journal-title":"Asia Pac J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki S","year":"2017","unstructured":"Suzuki S, Ishikawa N, Konoeda F, et al.. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology. 2017, 89:1127-34. 10.1212\/WNL.0000000000004359","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-022-05920-4","article-title":"Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice","volume":"43","author":"Villagr\u00e1n-Garc\u00eda M","year":"2022","unstructured":"Villagr\u00e1n-Garc\u00eda M, Velasco R. Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice. Neurol Sci. 2022, 43:2339-61. 10.1007\/s10072-022-05920-4","journal-title":"Neurol Sci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon AC","year":"2021","unstructured":"Guidon AC, Burton LB, Chwalisz BK, et al.. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. 2021, 9:e002890. 10.1136\/jitc-2021-002890","journal-title":"J Immunother Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s13256-021-02722-8","article-title":"Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report","volume":"15","author":"Tian CY","year":"2021","unstructured":"Tian CY, Ou YH, Chang SL, Lin CM. Pembrolizumab-induced myasthenia gravis-like disorder, ocular myositis, and hepatitis: a case report. J Med Case Rep. 2021, 15:244. 10.1186\/s13256-021-02722-8","journal-title":"J Med Case Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa H","year":"2019","unstructured":"Safa H, Johnson DH, Trinh VA, et al.. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019, 7:319. 10.1186\/s40425-019-0774-y","journal-title":"J Immunother Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe GI","year":"1999","unstructured":"Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999, 52:1487-9. 10.1212\/WNL.52.7.1487","journal-title":"Neurology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok G","year":"2016","unstructured":"Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother. 2016, 12:2777-89. 10.1080\/21645515.2016.1199310","journal-title":"Hum Vaccin Immunother"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow MA","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018, 378:158-68. 10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/cei\/uxac108","article-title":"Clinical features, diagnosis, and management of pembrolizumab-induced myasthenia gravis","volume":"211","author":"Zhao S","year":"2023","unstructured":"Zhao S, Zhou Y, Sun W, Li Z, Wang C. Clinical features, diagnosis, and management of pembrolizumab-induced myasthenia gravis. Clin Exp Immunol. 2023, 211:85-92. 10.1093\/cei\/uxac108","journal-title":"Clin Exp Immunol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00634","article-title":"Immune checkpoint inhibitor-induced myasthenia gravis","volume":"11","author":"Huang YT","year":"2020","unstructured":"Huang YT, Chen YP, Lin WC, Su WC, Sun YT. Immune checkpoint inhibitor-induced myasthenia gravis. Front Neurol. 2020, 11:634. 10.3389\/fneur.2020.00634","journal-title":"Front Neurol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13050989","article-title":"Immune-related adverse events (irAE) in cancer immune checkpoint inhibitors (ICI) and survival outcomes correlation: to rechallenge or not?","volume":"13","author":"Albandar HJ","year":"2021","unstructured":"Albandar HJ, Fuqua J, Albandar JM, Safi S, Merrill SA, Ma PC. Immune-related adverse events (irAE) in cancer immune checkpoint inhibitors (ICI) and survival outcomes correlation: to rechallenge or not?. Cancers (Basel). 2021, 13:989. 10.3390\/cancers13050989","journal-title":"Cancers (Basel)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni A","year":"2022","unstructured":"Chennamadhavuni A, Abushahin L, Jin N, Presley CJ, Manne A. Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors. Front Immunol. 2022, 13:779691. 10.3389\/fimmu.2022.779691","journal-title":"Front Immunol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis","volume":"8","author":"Wang PF","year":"2017","unstructured":"Wang PF, Chen Y, Song SY, et al.. Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol. 2017, 8:730. 10.3389\/fphar.2017.00730","journal-title":"Front Pharmacol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1372861","article-title":"Prognosis of immune checkpoint inhibitor-induced myasthenia gravis: a single center experience and systematic review","volume":"15","author":"Qin Y","year":"2024","unstructured":"Qin Y, Chen S, Gui Q, et al.. Prognosis of immune checkpoint inhibitor-induced myasthenia gravis: a single center experience and systematic review. Front Neurol. 2024, 15:1372861. 10.3389\/fneur.2024.1372861","journal-title":"Front Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/402366-early-onset-immune-checkpoint-inhibitor-induced-myasthenia-gravis-following-first-cycle-pembrolizumab-diagnostic-challenges-and-management-strategies","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T12:10:10Z","timestamp":1769861410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/402366-early-onset-immune-checkpoint-inhibitor-induced-myasthenia-gravis-following-first-cycle-pembrolizumab-diagnostic-challenges-and-management-strategies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,31]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.102693","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,31]]}}}